Pfizer (NYSE:PFE) Trading Down 2% – Here’s Why

Pfizer Inc. (NYSE:PFE) dropped 2% during mid-day trading on Friday . The stock traded as low as $27.02 and last traded at $27.03. Approximately 29,000,418 shares traded hands during mid-day trading, a decline of 37% from the average daily volume of 46,050,848 shares. The stock had previously closed at $27.57.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins are reshaping Pfizer’s pipeline: a partnered Phase 3 Lyme vaccine showed roughly ~75% efficacy and separate late‑stage oncology studies (including topline TALAPRO‑3 results for TALZENNA®) were positive — news that supports longer‑term revenue diversification beyond COVID products. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Pfizer announced positive topline Phase 3 TALAPRO‑3 results for TALZENNA® (PARP inhibitor combo), which could expand oncology revenue and help re‑rate investor expectations if approvals and launches follow. Pfizer Inc. (PFE) Announces Positive Topline Results From Phase 3 TALAPRO-3 Study of TALZENNA®
• Positive Sentiment: Guggenheim raised its price target modestly and reiterated a Buy, citing upcoming MEVPRO‑1 Phase 3 data — analyst optimism and a higher target can support the stock ahead of key readouts. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Several bullish commentaries (Seeking Alpha, analyst upgrades) argue Pfizer is an undervalued buy given its pipeline momentum and yield, which helped earlier session strength. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Market‑wide context: some articles explain recent session gains despite broader market weakness, noting Pfizer briefly outperformed as trial news and analyst notes circulated. These are situational and may not change fundamentals. Why the Market Dipped But Pfizer (PFE) Gained Today
• Neutral Sentiment: Commentators like Jim Cramer have highlighted Pfizer but signaled they want clearer visibility on product flow — a cautionary tone that may limit enthusiasm until revenue paths are clearer. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Negative Sentiment: Dividend safety concerns are resurfacing: articles note Pfizer’s high yield (~6%+) and argue payout mechanics deserve scrutiny, which can pressure income‑focused holders and limit multiple expansion. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Wall Street Analyst Weigh In

PFE has been the topic of a number of research reports. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. HSBC raised their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Daiwa Securities Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Trading Down 2.0%

The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a fifty day moving average price of $26.82 and a two-hundred day moving average price of $25.67. The firm has a market capitalization of $153.70 billion, a price-to-earnings ratio of 19.88 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 earnings per share. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of PFE. Stance Capital LLC boosted its holdings in Pfizer by 26,746.0% in the 4th quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock valued at $668,000 after purchasing an additional 26,746 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in shares of Pfizer by 27.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock worth $45,873,000 after buying an additional 392,913 shares during the last quarter. World Investment Advisors raised its position in shares of Pfizer by 11.2% during the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock valued at $9,909,000 after buying an additional 40,239 shares during the period. Nalls Sherbakoff Group LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $92,000. Finally, DUTCH ASSET Corp acquired a new position in Pfizer in the fourth quarter valued at approximately $237,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.